logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutCareersContact UsSecurity
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.
    1. Home
    2. Manufacturers
    3. Gilead Sciences, Inc.

    Gilead Sciences, Inc. drugs

    FiltersReset Filters
    18 results
    • biktarvy - bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate tablet

      (Bictegravir Sodium, Emtricitabine, And Tenofovir Alafenamide Fumarate)
      Medication Details
      Gilead Sciences, Inc.
      Medication Details
      Drug Interactions
    • cayston

      (aztreonam)
      Medication Details
      Gilead Sciences, Inc.
      Usage: CAYSTON® is indicated for improving respiratory symptoms in cystic fibrosis patients with Pseudomonas aeruginosa. It is not established for use in patients under 7, those with FEV1 <25% or >75%, or those colonized with Burkholderia cepacia. It should only be used in confirmed Pseudomonas infections.
      Medication Details
      Drug Interactions
    • complera

      (emtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate)
      Medication Details
      Gilead Sciences, Inc.
      Usage: COMPLERA® is indicated for treating HIV-1 in adults and children (≥35 kg) as initial therapy for those with no treatment history and HIV-1 RNA ≤100,000 copies/mL, or to replace a stable regimen in virologically suppressed patients. Limitations include risk of virologic failure in those with higher baseline HIV-1 RNA.
      Medication Details
      Drug Interactions
    • descovy

      (emtricitabine and tenofovir alafenamide)
      Medication Details
      Gilead Sciences, Inc.
      Usage: DESCOVY is indicated for the treatment of HIV-1 infection in adults and pediatric patients (≥35 kg) in combination with other antiretroviral agents. It is also approved for HIV-1 pre-exposure prophylaxis (PrEP) in at-risk adults and adolescents (≥35 kg), excluding those at risk from receptive vaginal sex.
      Medication Details
      Drug Interactions
    • emtriva

      (EMTRICITABINE)
      Medication Details
      Gilead Sciences, Inc.
      Usage: EMTRIVA® is indicated for the treatment of HIV-1 infection in combination with other antiretroviral agents.
      Medication Details
      Drug Interactions
    • epclusa - velpatasvir and sofosbuvir tablet, film coated

      (Velpatasvir And Sofosbuvir)
      Medication Details
      Gilead Sciences, Inc.
      Medication Details
    • genvoya

      (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide)
      Medication Details
      Gilead Sciences, Inc.
      Usage: GENVOYA is indicated for the treatment of HIV-1 infection in adults and pediatric patients (≥25 kg) with no prior antiretroviral treatment history or to replace an existing regimen in virologically-suppressed patients on a stable regimen for at least six months without treatment failures or resistance.
      Medication Details
      Drug Interactions
    • odefsey

      (emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide)
      Medication Details
      Gilead Sciences, Inc.
      Usage: ODEFSEY is indicated for the treatment of HIV-1 infection in patients weighing at least 25 kg, either as initial therapy for those with no prior treatment history and HIV-1 RNA ≤ 100,000 copies/mL, or to replace a stable regimen in virologically suppressed patients.
      Medication Details
      Drug Interactions
    • sovaldi - sofosbuvir tablet, film coated

      (Sofosbuvir)
      Medication Details
      Gilead Sciences, Inc.
      Medication Details
    • stribild

      (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate)
      Medication Details
      Gilead Sciences, Inc.
      Usage: STRIBILD® is indicated for treating HIV-1 in adults and pediatric patients aged 12 and older (weighing at least 35 kg) without prior antiretroviral treatment or to replace a stable regimen in those virologically suppressed for at least 6 months, without resistance to its components.
      Medication Details
      Drug Interactions